Harmonizing AIM estimates of PWLHIV

Guidance for triangulating data and estimates of HIV prevalence among pregnant women and

2 coverage of PMTCT using the Spectrum AIDS Impact Module

- 3 Running head: Harmonizing AIM estimates of PWLHIV
- ⁴ Magdalene K. Walters^{1§}, Eline L. Korenromp², Anna Yakusik², Ian Wanyeki², André Kaboré^{3,}
- 5 Arthur Poimouribou⁴, Célestine Ki⁴, Coumbo Dao⁵, Paul Bambara⁴, Salam Derme⁴,
- ⁶ Théophile Ouedraogo⁴, Kai Hon Tang¹, Marie-Claude Boily¹, Mary Mahy², Jeffrey W. Imai-
- 7 Eaton^{1,7}
- ⁸ ¹ MRC Centre for Global Infectious Disease Analysis, School of Public Health, Imperial
- 9 College London, London, United Kingdom
- ¹⁰ ² Data for Impact Department, Joint United Nations Programme on HIV/AIDS, Geneva,
- 11 Switzerland
- ¹² ³ Data for Impact Division, Joint United Nations Programme on HIV/AIDS, Ouagadougou,
- 13 Burkina Faso
- ⁴ Permanent Secretary of the National Council for the Fight against AIDS and Communicable
- 15 Infections, Burkina Faso
- ⁵ Direction de la Santé de la Famille (DSF), Ouagadougou, Burkina Faso

¹⁷ Center for Communicable Disease Dynamics, Department of Epidemiology, Harvard T.H.

18 Chan School of Public Health, Boston, MA, USA

19 Correspondence to: Magdalene Walters, Imperial College London, St. Mary's Hospital Campus,

20 Norfolk Place, London W2 1P, UK (email: <u>mwalters@ic.ac.uk</u>)

21 **Conflicts of Interest and Source of Funding:** The authors declare no conflicts of interest. This

- research was supported by the National Institute of Allergy and Infectious Diseases of the National
- Institutes of Health under award number 1R01AI152721-01A1, UNAIDS, and the MRC Centre for
- 24 Global Infectious Disease Analysis (reference MR/R015600/1), jointly funded by the UK Medical
- 25 Research Council (MRC) and the UK Foreign, Commonwealth & Development Office (FCDO), under
- the MRC/FCDO Concordat agreement and is also part of the EDCTP2 programme supported by the
- 27 European Union.
- A preliminary analysis of this work was virtually presented in October 2022 to the UNAIDS Reference
- 29 Group on HIV Estimates, Modelling, and Projections. For open access, the author has applied a
- 30 Creative Commons Attribution (CC BY) license to any Author Accepted Manuscript version arising.

31 **Main text word count:** 3571 (excluding headings)

Harmonizing AIM estimates of PWLHIV

32 Abstract

- 33 Background: Most countries use the Spectrum AIDS Impact Module (Spectrum-AIM),
- 34 antenatal care routine HIV testing, and antiretroviral treatment data to estimate HIV
- ³⁵ prevalence among pregnant women. Non-representative programme data may lead to
- ³⁶ inaccurate estimates HIV prevalence and treatment coverage for pregnant women.
- 37 Setting: 154 locations in 126 countries.
- 38 Methods: Using 2023 UNAIDS HIV estimates, we calculated three ratios: (1) HIV
- ³⁹ prevalence among pregnant women to all women 15-49y (prevalence), (2) ART coverage
- 40 before pregnancy to women 15-49y ART coverage (ART pre-pregnancy), and (3) ART
- 41 coverage at delivery to women 15-49y ART coverage (PMTCT coverage). We developed an
- algorithm to identify and adjust inconsistent results within regional ranges in Spectrum-AIM,
- 43 illustrated using Burkina Faso's estimates.
- 44 **Results:** In 2022, the mean regional ratio of prevalence among pregnant women to all
- 45 women ranged from 0.68 to 0.95. ART coverage pre-pregnancy ranged by region from 0.40
- to 1.22 times ART coverage among all women. Mean regional PMTCT coverage ratios
- ranged from 0.85 to 1.51. The prevalence ratio in Burkina Faso was 1.59, above the typical
- range 0.62-1.04 in western and central Africa. Antenatal clinics reported more PMTCT
- recipients than estimated HIV-positive pregnant women from 2015 to 2019. We adjusted
- ⁵⁰ inputted PMTCT programme data to enable consistency of HIV prevalence among pregnant
- 51 women from programmatic routine HIV testing at antenatal clinics with values typical for
- 52 Western and central Africa.
- 53 **Conclusion:** These ratios offer Spectrum-AIM users a tool to gauge the consistency of their
- 54 HIV prevalence and treatment coverage estimates among pregnant women with other
- 55 countries in the region.
- 56 Keywords: HIV; AIDS impact module; pregnant women; ART; PMTCT
- 57 Abstract word count: 248
- 58

Harmonizing AIM estimates of PWLHIV

59 Introduction

Estimates of HIV prevalence among pregnant women determine need for and coverage of 60 61 antiretrovirals for prevention of maternal to child transmission (PMTCT), a key input to estimating paediatric HIV infections and monitoring progress towards eliminating mother-to-62 child HIV transmission.¹⁻⁴ Most countries estimate the number of pregnant women living with 63 HIV (PWLHIV) and PMTCT coverage using the AIDS Impact Module in Spectrum 64 (Spectrum-AIM). Comparing related model outcomes and typical patterns across locations 65 can reveal inconsistencies in input data or model assumptions that may result in inaccurate 66 estimates. 67

Country-specific estimates of HIV prevalence among pregnant women are the result of a 68 multi-step modelling process in Spectrum-AIM. The number of PWLHIV is calculated by 69 multiplying the age-specific number of women living with HIV (WLHIV) in reproductive ages 70 (15 to 49 years [15-49y]), age-specific fertility rates (by 5-year age group), and the relative 71 fertility of WLHIV relative to women without HIV (fertility rate ratio [FRR]). Age-specific HIV 72 prevalence is derived by fitting a mathematical model to local HIV surveillance data,⁵⁻⁷ 73 including HIV prevalence from household surveys, prevalence among pregnant women 74 75 attending antenatal clinics (ANC), prevalence surveys among key populations, new HIV diagnoses, or AIDS-related deaths. Age-specific fertility rates are obtained from the United 76 Nations World Population Prospects.⁸ Relative fertility of WLHIV compared to women 77 without HIV by age, treatment-status, and local effects are estimated from national 78 household surveys in African countries that measure HIV status and collect birth histories.^{8,9} 79 Inconsistencies in population prevalence, fertility rates, or relative fertility among WLHIV may 80 vield inaccurate estimates of HIV prevalence and treatment coverage among pregnant 81 women within Spectrum-AIM. 82

Quality of information about HIV among pregnant women varies by region and epidemic 83 type. In most African countries with high HIV prevalence, ANC attendance and routine HIV 84 testing at ANC (ANC-RT) is nearly universal. Universal HIV testing at ANC provides direct 85 measures of HIV prevalence among pregnant women. Spectrum-AIM calculates a 'local 86 adjustment factor' (LAF) to calibrate the modelled prevalence among pregnant women to 87 HIV prevalence measured from national ANC-RT. The default LAF value of 1.0 indicates that 88 the fertility of WLHIV is consistent with the default HIV FRR estimated from household 89 90 survey data. In the 2023 UNAIDS estimates, most sub-Saharan African (SSA) locations (n=36/43) calibrated the LAF to ANC-RT data.^{10,11} 91

In countries with low HIV prevalence and transmission primarily among key populations and
 their partners, mostly outside SSA, ANC HIV testing coverage varies and is often prioritised

Harmonizing AIM estimates of PWLHIV

94 among higher risk women or higher burden locations. Consequently, HIV prevalence from 95 ANC-RT in these locations does not represent prevalence among all pregnant women and cannot be used to calibrate the LAF.^{12–18} Data are limited about WLHIV's fertility relative to 96 women without HIV in these settings, and fertility may be more heterogeneous given the 97 greater concentration of HIV among populations such as sex workers, partners of men who 98 have sex with men, and people who inject drugs. Because the default FRRs were derived 99 from household surveys in SSA countries, they may mis-specify fertility of WLHIV in other 100 regions. Lacking representative measures of HIV prevalence among pregnant women, some 101 Spectrum-AIM users manually adjust the LAF so that modelled estimates of PWLHIV are 102 greater than numbers of PWLHIV receiving ARVs from programme data. In non-SSA 103 regions, more than half of all countries with results published by UNAIDS in 2023 (n=52/83) 104 manually changed the LAF.^{10,11} 105

106 Large adjustments to the default fertility patterns or uncharacteristically large differences 107 between related model outputs could indicate inaccurate model estimates, inaccurate input data, or inappropriate interpretations of data sources. To identify possible challenges, we 108 used UNAIDS estimates from Spectrum-AIM published in 2023 to establish patterns for HIV 109 110 prevalence and treatment coverage among pregnant women for each region. We also 111 proposed an algorithm to guide Spectrum-AIM users to critically review the consistency of programmatic estimates with regional patterns and scrutinize surveillance data. 112 programmatic input, and model assumptions.^{10,11} As a case study, we applied the approach 113 114 and described its impact on estimates of HIV prevalence among pregnant women using 115 Spectrum-AIM estimates for Burkina Faso.

116 Methods

117 We used Spectrum-AIM files submitted by HIV estimation teams to UNAIDS for publication in 2023 to calculate three ratios: (1) HIV prevalence among pregnant women to HIV 118 prevalence among all women 15-49y ('prevalence ratio'), (2) ART coverage among PWLHIV 119 before the current pregnancy to ART coverage among WLHIV 15-49y ('ART coverage pre-120 121 pregnancy ratio'), and (3) the ratio of ART coverage in PWLHIV at delivery to ART coverage in WLHIV 15-49y ('PMTCT coverage ratio'). We reported these ratios for the year 2022, as 122 they did not vary substantially over the past decade. We summarised ranges for each ratio 123 by UNAIDS region. Values outside of these ranges may indicate inconsistent data for the 124 number of pregnant women on ART, number of PWLHIV, or low predictive power of the local 125 HIV surveillance data to estimate HIV prevalence in the general population. 126

Harmonizing AIM estimates of PWLHIV

127 Data sources

We extracted outputs from 154 publicly available national or subnational publicly available 128 Spectrum-AIM HIV estimates files submitted by 126 countries and published by UNAIDS in 129 2023.11 Three SSA countries had subnational files (Kenya, Zimbabwe, Ethiopia); the 130 remaining 123 files represented national HIV epidemics created by country teams and 131 submitted to UNAIDS for review and publication. Spectrum-AIM methods are described 132 elsewhere.^{19–21} Briefly, in countries with high HIV prevalence (n= 64, mostly in SSA, 133 including Burkina Faso), adult HIV prevalence and incidence trends were estimated from 134 data on HIV prevalence among (1) nationally-representative samples of adults from 135 136 household-based surveys and (2) pregnant women attending ANC, sampled in periodic sentinel surveillance up to the mid-2010s and more recently from ANC-RT data.⁵ In 137 countries with lower HIV prevalence, epidemic trends were fit to national HIV and/or AIDS 138 case reports and AIDS-related deaths reported through vital registration with the CSAVR or 139 ECDC models (n= 46) or from HIV prevalence survey and surveillance data among risk 140 groups using the EPP concentrated (n= 27) or AEM models (n= 12).^{6,7} All incidence models 141 accounted for the effects of ART on survival and transmission. Locations and the estimation 142 method for each are reported in Supplementary Table S1. 143

- 144 Spectrum-AIM calculates HIV prevalence among pregnant women from age-specific HIV
- prevalence of all women 15-49y, age-specific fertility rates,⁸ and HIV fertility rate ratios.⁹
- 146 Data on HIV FRRs outside SSA are limited and therefore default HIV FRR patterns for SSA
- are applied to all regions, despite very different risk populations and contraceptive use. We
- extracted Spectrum-AIM's estimates for HIV prevalence among women 15-49y, HIV
- prevalence among pregnant women, ART coverage among WLHIV 15-49y, and initiation
- timing for PWLHIV on ART for 2022. We compared HIV prevalence among pregnant women
- and women 15-49y to nationally representative surveys where available (Supplementary
- 152 Table S2 and Supplementary Figure S1).
- 153 HIV prevalence, ART, and PMTCT ratios

156

We calculated the 'prevalence ratio' for all Spectrum-AIM files by dividing the HIV prevalence
 among pregnant women by the HIV prevalence among women 15-49y (equation 1):

$$Prevalence\ ratio = \frac{HIV\ prevalence\ among\ pregnant\ women}{HIV\ prevalence\ among\ women\ aged\ 15-49\ years\ old}$$

Equation 1

- 157 The 'ART coverage pre-pregnancy ratio' was calculated as the proportion of PWLHIV on
- ART before the current pregnancy from programmatic input and Spectrum-AIM's estimate of
- ¹⁵⁹ PWLHIV, divided by ART coverage among WLHIV 15-49y (equation 2):

Harmonizing AIM estimates of PWLHIV

$$ART \ coverage \ pre-pregnancy \ ratio = \frac{ART \ coverage \ before \ pregnancy \ among \ all \ PWLHIV}{ART \ coverage \ for \ all \ WLHIV \ aged \ 15-49 \ years}$$

160

161 The 'PMTCT coverage ratio' was the ratio of total ART coverage (i.e., proportion of PWLHIV

who received ART during the pregnancy, started before or during the current pregnancy)

and ART coverage for WLHIV 15-49y (equation 3):²⁴

$$PMTCT \ coverage \ ratio = \frac{ART \ coverage \ at \ delivery \ amongst \ all \ PWLHIV}{ART \ coverage \ for \ all \ WLHIV \ aged \ 15 - 49 \ years}$$

164

Equation 3

Equation 2

165 Identifying typical ranges and outliers by region

We calculated the mean of each ratio by UNAIDS-defined regions, broadly representing 166 167 variations in epidemic type: eastern and southern Africa (ESA), western and central Africa (WCA), Latin America and Caribbean (LAC), Asia and Pacific (AP), eastern Europe and 168 central Asia (EECA), western and central Europe and North America (WCENA), middle East 169 and northern Africa (MENA). For ESA and WCA, we considered location-specific ratios 170 171 between 0.75 times lower to 1.25 times higher than the regional mean as 'typical' and those outside this range to be outliers. For other regions, we present these ranges but emphasize 172 the influence of local HIV surveillance data on estimating HIV prevalence among pregnant 173 women. Alternate methods to define typical ranges were considered (Supplementary Text 174 175 S1).

For countries where transmission primarily occurs outside of key populations, we expected 176 prevalence ratios to be less than one (i.e., lower HIV prevalence among pregnant women 177 than all women 15-49y),^{25,26} and the ART pre-pregnancy ratios (on ART before pregnancy) 178 to be less than one, because PWLHIV are on average younger and so acquired HIV more 179 recently.^{27,28} We expected PMTCT coverage ratios to be above one in countries with high 180 ANC-RT coverage and ART for PMTCT uptake, as pregnant women who were untreated 181 before pregnancy should be diagnosed and initiated on ART through ANC-RT.²⁹ Outside of 182 183 SSA, where HIV transmission is mostly among key populations and their partners, and fertility and contracepting patterns are different from SSA, there was little a priori information 184 about expected typical relationships for the prevalence, ART pre-pregnancy, or PMTCT 185 ratios. 186

We further hypothesized that countries with outlier prevalence, ART coverage, or PMTCT
 coverage ratios had atypical LAFs that were fitted or modified to reconcile discrepant data on
 HIV prevalence among pregnant women (whether fit to ANC-RT data or estimated by

Harmonizing AIM estimates of PWLHIV

190 Spectrum-AIM) and number of PWLHIV on ART from programmes. Alternatively, if the

191 distribution of LAFs across countries within a region systematically differed from one, this

may indicate that the regional HIV-related FRR parameters in Spectrum-AIM are mis-192 specified.

194 To test these hypotheses, we calculated an average LAF by region, weighted according to how close location-specific prevalence, ART pre-pregnancy, and PMTCT ratio (Ratio₁) were 195 to the regional mean ratio ($Ratio_{R}$). The inverse favours values that are closest to the 196 regional mean ratio. Weighted regional LAFs were calculated separately for all ratios. 197

$$w_L = \frac{1}{|Ratio_L - Ratio_R|}$$

198

199

193

$$LAF_R = \frac{\sum_C w_L * LAF_L}{\sum_C w_L}$$

Equation 5

Equation 4

Lastly, we identified inconsistent ART coverage among WLHIV 15-49y and PWLHIV. 200 Inconsistent coverage estimates consisted of: (1) more women receiving ART than 201 estimated WLHIV and (2) large year-to-year differences in the number of women receiving 202 ART. The first indicated inaccurate programme data or modelled output depending on the 203 204 location, the second indicated possible data recording issues and programmatic changes that should be verified by those familiar with local context. 205

Guidance for reviewing data and model outputs with Burkina Faso case study 206

From the outlier analysis, we developed a six-step algorithm to assess data and model 207 assumptions regarding HIV prevalence and ART coverage among pregnant women (Figure 208 We applied the algorithm using a preliminary Spectrum-AIM file produced by Burkina 209 210 Faso (WCA region) for the 2023 round of UNAIDS published estimates. This file represents the most up-to-date surveillance and treatment data from the national HIV programme and 211 estimates. 212 213 This study was reviewed and approved by the Research Governance and Integrity team of Imperial College London (ICREC #6300528). 214

Harmonizing AIM estimates of PWLHIV

215 **Results**

216 Prevalence, ART pre-pregnancy, and PMTCT ratios

In 2022, the mean prevalence ratio was less than one in all regions, ranging from 0.68 in the 217 MENA region to 0.95 in the LAC region (Table 1), indicating that pregnant women typically 218 had lower HIV prevalence than women 15-49y. The ESA and WCA regions had mean 219 220 prevalence ratios of 0.72 and 0.83, respectively (Table 1). WCA had a higher proportion of outliers than ESA (Figure 2; ESA: 6/46; WCA: 5/25). The regional mean ART coverage pre-221 pregnancy ratio was lowest in WCA at 0.40, and less than one for all regions, except 222 WCENA and EECA where it was 1.22 and 1.06, respectively (Table 1). Twenty-two countries 223 had ART coverage pre-pregnancy ratios above one (Figure 3). The mean ART coverage 224 pre-pregnancy ratio across all locations was 0.83 and the mean PMTCT coverage ratio was 225 1.21, and in all regions the mean PMTCT coverage ratio exceeded the ART coverage pre-226 pregnancy ratio. For all regions except WCA (0.85), the PMTCT coverage ratio exceeded 227 228 one.

229 Atypical ratios within regions

All regions had countries with prevalence ratios outside of the regional typical range (Table 1). Globally, 19 of 154 locations (11 national locations, 8 subnational locations across Ethiopia, Kenya, and Zimbabwe) reported more PWLHIV receiving ART than the estimated number of PWLHIV in 2022. Of these 19 locations, two countries reported more pregnant women on ART before the current pregnancy than total estimated PWLHIV. Every region had countries with ART pre-pregnancy ratios outside of 0.75 – 1.25 times the mean ART pre-pregnancy ratio regional range (Figure 2).

237 Burkina Faso case study

We applied the data review steps described in Figure 1 to the Burkina Faso Spectrum-AIM 238 file. Burkina Faso calibrated HIV prevalence among pregnant women to HIV prevalence from 239 ANC-RT data. Prevalence from routine ANC testing in 2022 was 1.19%; Spectrum estimated 240 HIV prevalence among all women 15-49y as 0.7% (0.6 - 0.9%). This differed from the typical 241 relationship where prevalence among pregnant women was less than HIV prevalence 242 among all women.¹⁰ Step one of the process (Figure 1) revealed that the prevalence ratio in 243 244 Burkina Faso (1.56) exceeded the typical range for WCA (0.62-1.04, Figure 2). Step two identified Burkina Faso's LAF parameter of 2.15 was greater than the typical LAF in the 245 region (1.12, Table 1). The third step situated Burkina Faso among countries with a national 246 household survey that informed FRR parameter estimates in Spectrum-AIM, indicating that 247 248 the default FRR parameters should represent the relative fertility of WLHIV in Burkina Faso.

Harmonizing AIM estimates of PWLHIV

Because both the prevalence ratio and LAF were higher than typical for WCA, we
 determined that the ANC-RT reported HIV prevalence was higher than expected for a
 country in WCA.

The Burkina Faso ratios for ART coverage pre-pregnancy (0.47) and PMTCT coverage 252 253 (1.00) were both within typical ranges for WCA (0.30 - 0.50 for ART pre-pregnancy and 0.64 - 1.06 for PMTCT ratios in WCA, Table 1). We did not find inconsistencies in ART coverage 254 among WLHIV 15-49y in step four. The steps to detect inconsistencies in PMTCT 255 programme data inputs (five and six) indicated the number of WLHIV on PMTCT exceeded 256 257 the modelled number of PWLHIV in each year between 2015 and 2020 (Figure 4). The discrepancy between pregnant women reported on ART at delivery and estimated number 258 PWLHIV was largest in 2019, when the reported number of PWLHIV on ART at delivery 259 treatment was 1.67 times Spectrum-AIM's estimate of PWLHIV. Between 2014 and 2015, 260 261 the reported number of WLHIV receiving PMTCT tripled from 4,285 to 12,937.

The steps outlined in Figure 1 suggested two potential adjustments to reconcile Burkina 262 Faso's estimates of HIV prevalence among pregnant women: (1) HIV prevalence among 263 pregnant women compared to all women 15-49y was higher than typical for countries in 264 265 WCA and (2) the number of PWLHIV receiving treatment was inconsistent with the 266 estimated PWLHIV. Both discrepancies could be explained by the inaccurately large number of reported PWLHIV on ART before current pregnancy, which could occur if some PWLHIV 267 on ART were double counted. Per the guidance in steps one and two, we decreased Burkina 268 Faso's LAF from 2.15 (fit to ANC-RT data) to 1.12 (WCA regional estimate), as an initial step 269 270 to align Burkina Faso's prevalence ratio with regional estimates. During steps three and four, we did not change the FRR or ART coverage among women 15-49y, since Burkina Faso's 271 272 FRR was fit to national household survey data, and we did not identify inconsistencies in ART coverage among women 15-49y. Because the PMTCT ratio was within the range of 273 274 typical values for WCA (Table 1), we applied the reported distribution of ART initiation timings annually to ART coverage among women 15-49y to produce new to the overall level 275 of PMTCT coverage (Figure 4, and Supplementary Text S2). Reducing the LAF and 276 updating the number of women receiving antiretrovirals for PMTCT resulted in a new 277 278 prevalence ratio of 1.07, consistent with other countries in the region.

279 Discussion

Our study assessed estimates of HIV prevalence and treatment coverage among pregnant women compared to all adult women by global regions. We developed a data review process for Spectrum-AIM users to assess the relationship between ANC and ART related programme data inputs and assumptions about fertility among WLHIV. This algorithm relies

Harmonizing AIM estimates of PWLHIV

on three ratios (prevalence, ART coverage pre-pregnancy, and PMTCT coverage),

prompting users to interrogate discrepancies between programme and surveillance data and

286 Spectrum-AIM assumptions and to align estimates of HIV prevalence among pregnant

women and ART coverage at delivery with other locations in the region.

288 HIV prevalence among pregnant women in 2022 was lower than among all women 15-49y in all regions, typically by 20-30%. Prevalence ratios showed less variation across countries in 289 regions with larger HIV epidemics compared to regions with transmission more concentrated 290 among key populations and their partners. The greater variation in the latter is likely due to 291 292 diverse epidemiological factors and variations in surveillance data reliability and estimation approaches. There are three notable differences in the respective groups' Spectrum-AIM 293 models and input data: (1) most countries in SSA use the same type of data (HIV testing 294 from ANC and representative household surveys) to fit overall adult HIV prevalence, 295

whereas concentrated epidemic countries use surveillance among key populations (primarily non-ANC) data, (2) for countries that do use ANC data outside of SSA, HIV testing at ANC is often targeted at women at higher risk to HIV,^{30,31} and (3) default FRRs were derived from household survey data from SSA and may be more applicable there.

300 In most regions, ART coverage before pregnancy was lower than ART coverage among all 301 adult WLHIV, but by varying degrees (regional means ranging 0.40 - 0.87, excluding EECA 302 and WCENA). ART coverage before pregnancy was higher in EECA (1.06) and WCENA 303 (1.22). All countries in EECA and WCENA with ART pre-pregnancy ratios greater than one were estimated with the CSAVR model, which uses national HIV diagnoses and/or AIDS 304 case reports and AIDS-related deaths reported through vital registration to estimate age-305 specific HIV prevalence (Supplementary Table S1).⁶ Assessing typical results for the 306 prevalence, ART coverage pre-pregnancy, and PMTCT ratios for countries without data that 307 directly measures HIV prevalence among pregnant women requires more nuance than for 308 309 countries with ANC-RT data.

Interpreting outlier ratios involves scrutinizing both local HIV surveillance data for total
 population prevalence estimation and its implications for estimating HIV prevalence among
 pregnant women.

Countries should assess the reliability of data used to estimate age-specific HIV
 prevalence among adults, considering documented biases in HIV surveillance data.^{32–}
 ³⁵ Where death registration data are used, countries should consider how frequent
 misclassification of cause of death is.³⁵

If data on PMTCT provision is reliable, countries could consider manual adjustments
 to the LAF to align the number of PWLHIV with the reported number of PWLHIV on

Harmonizing AIM estimates of PWLHIV

ART from programmes. More work should be done to estimate the relative fertility of
 WLHIV in that epidemic setting rather than using the FRR estimated from SSA
 household surveys.

While the proposed ratios describe relationships between surveillance data, programmatic 322 323 input, and model assumptions, they are intrinsically linked through the model and cannot be 324 evaluated independently. Aligning one ratio with the mean regional value may cause another ratio to diverge from the regional value; balancing these ratios requires an iterative process 325 of assessing the accuracy of different input data sources and making justified adjustments. 326 327 While there is no gold standard source to compare these ratios to, using ratios calculated from external sources (such as PHIA and/or DHS surveys) in conjunction with regional 328 ranges to identify outliers is a starting point to scrutinizing implausible model inputs. 329

The Burkina Faso case study illustrates this. Burkina Faso's prevalence ratio was higher 330 than many locations in the WCA region accompanied by a high LAF fit to national ANC-RT 331 data. The atypically high prevalence ratio suggested that Burkina Faso's ANC-RT data 332 overstated HIV prevalence among pregnant women relative to all women 15-49y. Previous 333 studies found ANC testing clinics in Burkina Faso disproportionately serve urban areas with 334 higher HIV prevalence among pregnant women than national HIV prevalence among 335 pregnant women.³⁶ The difference in clientele is corroborated by lower access to multiple 336 ANC visits before delivery in rural areas of Burkina Faso.^{36,37} Ultimately, the Burkina Faso 337 estimation team determined the programme data were not robust for use in HIV estimation 338 indicated by low concordance between prevalence values from routine programme data and 339 sentinel surveillance data. 340

We suggest Spectrum-AIM users complete this review during the annual UNAIDS-supported 341 HIV estimation process. Regions with epidemics primarily among key populations will have 342 more heterogeneous fertility among WLHIV and access to care than countries with 343 transmission among the heterosexual population.³⁹⁻⁴² In this case, adjustments based on 344 regional trends may be less appropriate and Spectrum-AIM users should prioritize insights 345 about the local epidemic context and ANC coverage data to inform the more accurate 346 estimates of HIV prevalence and ART coverage among pregnant women. Additionally, 347 countries should triangulate results with additional valid data sources, including testing of 348 HIV exposed infants with mother infant pairing.⁴³⁻⁴⁵ Future work should examine patterns 349 across epidemic types and the relationship between pregnant women and key population 350 HIV prevalence to improve internal consistency in Spectrum-AIM's estimates of HIV 351 352 prevalence among pregnant women. Investing in validation with external data not input to the Spectrum-AIM model will produce more accurate estimates of HIV prevalence among 353

Harmonizing AIM estimates of PWLHIV

pregnant women and number of vertical HIV transmissions. Such data triangulation is well
 illustrated by Sibanda *et al.*, who integrated data from four sources (including Spectrum-AIM
 results) to identify gaps in the PMTCT care cascade in Zimbabwe, improving programme
 results.⁴⁶

³⁵⁸ Our work provides recommendations and a standardized approach to examining and, where

needed, improving estimates of HIV prevalence among pregnant women within the

360 Spectrum-AIM modelling process. We provide a path forward for targeted data collection and

quality review for further refining these parameterizations. Future work could expand this

analysis to include metrics measured through other data systems, such as early infant

diagnosis and vital registration. Improvements in estimates of the number of pregnant

364 women with HIV will aid measuring and addressing PMTCT needs, thereby decreasing

instances of vertical transmission, towards the elimination of maternal to child transmission.

Harmonizing AIM estimates of PWLHIV

366 **Tables and Figures**


Table 1. Typical ranges of prevalence ratios (defined as HIV prevalence among pregnant
 women to HIV prevalence among women 15-49y), ART pre-pregnancy (defined as ART
 coverage among PWLHIV at first ANC to ART coverage among WLIHV 15-49y), and
 PMTCT (defined as ART coverage started before or during the pregnancy among PWLHIV
 to ART coverage among WLHIV 15-49y) ratios

Ratio	UNAIDS Region	Mean (Standard Deviation)	Typical range (0.75 - 1.25x mean)	Typical local adjustment factor ¹
Prevalence	Eastern and southern Africa	0.72 (0.20)	(0.54 - 0.90)	1.02
	Western and central Africa	0.83 (0.24)	(0.62 - 1.04)	1.12
	Latin America and Caribbean	0.95 (0.29)	(0.71 - 1.18)	1.62 ²
	Asia and Pacific	0.73 (0.41)	(0.55 - 0.92)	1.07 ²
	Eastern Europe and central Asia	0.73 (0.24)	(0.55 - 0.91)	1.28 ²
	Western and central Europe and North America	0.70 (0.17)	(0.53 - 0.88)	1.07 ²
	Middle East and northern Africa	0.68 (0.21)	(0.51 - 0.84)	1.08 ²
ART pre- pregnancy coverage	Eastern and southern Africa	0.69 (0.17)	(0.52 - 0.87)	0.99
	Western and central Africa	0.40 (0.16)	(0.30 - 0.50)	1.27
	Latin America and Caribbean	0.67 (0.32)	(0.50 - 0.84)	1.69 ²
	Asia and Pacific	0.81 (0.36)	(0.61 - 1.01)	1.21 ²
	Eastern Europe and central Asia	1.06 (0.25)	(0.79 - 1.32)	1.29 ²
	Western and central Europe and North America	1.22 (0.42)	(0.91 - 1.52)	1.08 ²
	Middle East and northern Africa	0.84 (0.45)	(0.63 - 1.05)	1.37 ²
PMTCT coverage	Eastern and southern Africa	1.04 (0.26)	(0.78 - 1.30)	1.02
	Western and central Africa	0.85 (0.32)	(0.64 - 1.06)	1.19
	Latin America and Caribbean	1.19 (0.48)	(0.89 - 1.48)	2.14 ²
	Asia and Pacific	1.08 (0.55)	(0.81 - 1.35)	1.05 ²
	Eastern Europe and central Asia	1.51 (0.40)	(1.13 - 1.89)	1.61 ²
	Western and central Europe and North America	1.47 (0.49)	(1.10 - 1.84)	1.16 ²
	Middle East and northern Africa	1.34 (0.95)	(1.00 - 1.67)	1.20 ²

¹Method for calculating detailed in section S1 and Table S4 of SDC

³⁷³ ²Not calibrated to routine HIV testing done at ANC data

Harmonizing AIM estimates of PWLHIV




374

Figure 1. Recommendations to align Spectrum-AIM estimates of HIV prevalence and

treatment coverage of pregnant women with regional means.

Harmonizing AIM estimates of PWLHIV




Dotted red lines represent +/- 25% of the regional mean

Figure 2. Prevalence, ART pre-pregnancy, and PMTCT ratio by region. Points on the x-axis
represent distribution of ratios for all locations. Red dashed lines represent typical ranges of
each ratio by region calculated as 0.75 – 1.25 times the mean value. Curved lines show
density of ratios by region, with more common ratios represented as peaks. Multimodal
distributions represent within region heterogeneity of ratios, meaning the 'typical' ranges
should be interpreted with caution.

Coverage type
ART, women 15-49


Harmonizing AIM estimates of PWLHIV



PMTCT

Figure 3. Difference between ART coverage among WLHIV 15-49y and ART coverage at 385 delivery in 2022 for all countries analysed (grouped by region). Length of line indicates size 386 of difference for a given country, colour of line indicates whether ART coverage or PMTCT 387 coverage was higher, and shape of dot indicates the type of coverage. 388

Harmonizing AIM estimates of PWLHIV



Black line is ART coverage women 15-49y

Figure 4. Adjustment of PMTCT programme data for Burkina Faso, shown as the implied percentage coverage relative to Spectrum-AIM-estimated PWLHIV. Bars show estimated PMTCT coverage by regimen; and the line shows ART coverage among all WLHIV 15-49y for comparison. Left: using original PMTCT programme data; right: adjustment to address outcomes of the alignment assessment (Figure 1), as described in section S2 of SDC, bold outlining indicates a modelled value.

Harmonizing AIM estimates of PWLHIV

397 **References**

- Mahy M, Stover J, Kiragu K, *et al.* What will it take to achieve virtual elimination of motherto-child transmission of HIV? An assessment of current progress and future needs. *Sex Transm Infect* 2010; **86**: ii48–55.
- Taylor M, Newman L, Ishikawa N, *et al.* Elimination of mother-to-child transmission of HIV
 and Syphilis (EMTCT): Process, progress, and program integration. *PLOS Med* 2017; 14:
 e1002329.
- Thisyakorn U. Elimination of mother-to-child transmission of HIV: lessons learned from
 success in Thailand. *Paediatr Int Child Health* 2017; **37**: 99–108.
- 4 World Health Organization. Global guidance on criteria and processes for validationelimination of mother-to-child transmission of HIV, syphilis and hepatitis B virus. World
 408 Health Organization, 2021 https://www.who.int/publications-detailredirect/9789240039360 (accessed Dec 4, 2023).
- 5 Eaton JW, Brown T, Puckett R, *et al.* The Estimation and Projection Package Age-Sex
 Model and the r-hybrid model: new tools for estimating HIV incidence trends in subSaharan Africa. *AIDS Lond Engl* 2019; **33**: S235.
- Mahiane SG, Eaton JW, Glaubius R, Case KK, Sabin KM, Marsh K. Updates to
 Spectrum's case surveillance and vital registration tool for HIV estimates and projections.
 J Int AIDS Soc 2021; 24: e25777.
- Ghys PD, Brown T, Grassly NC, *et al.* The UNAIDS Estimation and Projection Package: a software package to estimate and project national HIV epidemics. *Sex Transm Infect* 2004; **80**: i5–9.
- 419 8 United Nations. World Population Prospects 2022: Summary of Results. United Nations,
 2022 DOI:10.18356/9789210014380.
- 421 9 Lewis JJC, Ronsmans C, Ezeh A, Gregson S. The population impact of HIV on fertility in
 422 sub-Saharan Africa. *AIDS Lond Engl* 2004; **18 Suppl 2**: S35-43.
- 10AIDSinfo | UNAIDS. https://aidsinfo.unaids.org/ (accessed March 1, 2023).
- 11 UNAIDS 2023 Report. UNAIDS Glob. Rep. 2023. https://thepath.unaids.org/ (accessed
 Nov 30, 2023).
- 12 El Bcheraoui C, Zúñiga-Brenes P, Ríos-Zertuche D, *et al.* Health system strategies to
 increase HIV screening among pregnant women in Mesoamerica. *Popul Health Metr* 2018; **16**: 5.
- 13Kendall T. Consequences of Missed Opportunities for HIV Testing during Pregnancy and
 Delayed Diagnosis for Mexican Women, Children and Male Partners. *PLOS ONE* 2014; 9:
 e109912.
- 14 Hensen B, Baggaley R, Wong VJ, *et al.* Universal voluntary HIV testing in antenatal care
 settings: a review of the contribution of provider-initiated testing & counselling. *Trop Med Int Health* 2012; **17**: 59–70.

Harmonizing AIM estimates of PWLHIV

435 15Hone S, Li L, Lee S-J, Comulada WS, Detels R. Progress and Challenges of 436 Implementing Decentralized HIV Testing For Prevention of Mother-to-Child Transmission of HIV – Myanmar. Int J Matern Child Health AIDS 2019; 8: 44–53. 437 16Chu D-T, Vo H-L, Tran D-K, et al. Socioeconomic Inequalities in the HIV Testing during 438 Antenatal Care in Vietnamese Women. Int J Environ Res Public Health 2019; 16: 3240. 439 17Pendse R, Gupta S, Yu D, Sarkar S. HIV/AIDS in the South-East Asia region: progress 440 and challenges. J Virus Erad 2016; 2: 1–6. 441 18Fakoya I, Arco DA, Copas AJ, et al. Factors Associated With Access to HIV Testing and 442 Primary Care Among Migrants Living in Europe: Cross-Sectional Survey. JMIR Public 443 Health Surveill 2017; 3: e7741. 444 19 Stover J, Glaubius R, Kassanjee R, Dugdale CM. Updates to the Spectrum/AIM model for 445 the UNAIDS 2020 HIV estimates. J Int AIDS Soc 2021; 24: e25778. 446 20 Stover J, Glaubius R, Mofenson L, et al. Updates to the Spectrum/AIM model for 447 estimating key HIV indicators at national and subnational levels. AIDS 2019; 33: S227. 448 21 Stover J, Glaubius R. Methods and Assumptions for Estimating Key HIV Indicators in the 449 UNAIDS Annual Estimates Process. JAIDS J Acquir Immune Defic Syndr 2024; 95: e5. 450 22The DHS Program - HIV Prevalence Surveys. https://www.dhsprogram.com/topics/HIV-451 Corner/hiv-prev/survey.cfm (accessed June 5, 2023). 452 23Sachathep K, Radin E, Hladik W, et al. Population-based HIV Impact Assessments 453 (PHIA) Survey Methods, Response, and Quality in Zimbabwe, Malawi, and Zambia. J 454 Acquir Immune Defic Syndr 1999 2021; 87: S6–16. 455 24 McNairy ML, Teasdale CA, El-Sadr WM, Mave V, Abrams EJ. Mother and Child Both 456 457 Matter: Re-conceptualizing the PMTCT Care Continuum. Curr Opin HIV AIDS 2015; 10: 403–10. 458 25 Mmbaga EJ, Leyna GH, Mnyika KS, Klepp K-I. Comparison of HIV-1 prevalence and risk 459 factors between pregnant, non-pregnant, all women and the general population in 460 Tanzania: implications for second-generation surveillance. Int J STD AIDS 2009; 20: 483-461 8. 462 463 26Zaba B, Boerma T, White R. Monitoring the AIDS epidemic using HIV prevalence data among young women attending antenatal clinics: prospects and problems. AIDS 2000; 464 **14**: 1633. 465 27Ng'ambi WF, Collins JH, Colbourn T, et al. Socio-demographic factors associated with 466 early antenatal care visits among pregnant women in Malawi: 2004–2016. PLoS ONE 467 2022; 17: e0263650. 468 469 28 Rurangirwa AA, Mogren I, Nyirazinyoye L, Ntaganira J, Krantz G. Determinants of poor utilization of antenatal care services among recently delivered women in Rwanda; a 470 population based study. BMC Pregnancy Childbirth 2017; 17: 142. 471 29 Awopegba OE, Kalu A, Ahinkorah BO, Seidu A-A, Ajayi AI. Prenatal care coverage and 472 correlates of HIV testing in sub-Saharan Africa: Insight from demographic and health 473 surveys of 16 countries. PLoS ONE 2020; 15: e0242001. 474

30 Ippoliti NB, Nanda G, Wilcher R. Meeting the Reproductive Health Needs of Female Key

Harmonizing AIM estimates of PWLHIV

475

Populations Affected by HIV in Low- and Middle-Income Countries: A Review of the 476 Evidence. Stud Fam Plann 2017; 48: 121-51. 477 31 Hermez J, Petrak J, Karkouri M, Riedner G. A review of HIV testing and counseling 478 policies and practices in the Eastern Mediterranean Region. AIDS 2010; 24: S25. 479 32 Mishra V. HIV testing in national population-based surveys: experience from the 480 Demographic and Health Surveys. Bull World Health Organ 2006; 84: 537–45. 481 33 Jahun I, Ehoche A, Bamidele M, et al. Evaluation of accuracy and performance of self-482 reported HIV and antiretroviral therapy status in the Nigeria AIDS Indicator and Impact 483 Survey (2018). PLoS ONE 2022; 17: e0273748. 484 34 Chasimpha SJD, Mclean EM, Dube A, McCormack V, dos-Santos-Silva I, Glynn JR. 485 Assessing the validity of and factors that influence accurate self-reporting of HIV status 486 after testing: a population-based study. AIDS Lond Engl 2020; 34: 931-41. 487 35Kyu HH, Jahagirdar D, Cunningham M, et al. Accounting for misclassified and unknown 488 cause of death data in vital registration systems for estimating trends in HIV mortality. J 489 Int AIDS Soc 2021; 24 Suppl 5: e25791. 490 36 Mwase T, Brenner S, Mazalale J, et al. Inequities and their determinants in coverage of 491 492 maternal health services in Burkina Faso. Int J Equity Health 2018; 17: 58. 37Tanou M, Kamiya Y. Assessing the impact of geographical access to health facilities on 493 maternal healthcare utilization: evidence from the Burkina Faso demographic and health 494 survey 2010. BMC Public Health 2019; 19: 838. 495 38 Helleringer S. Understanding the Adolescent Gap in HIV Testing Among Clients of 496 Antenatal Care Services in West and Central African Countries. AIDS Behav 2017; 21: 497 498 2760-73. 39Cernigliaro D, Barrington C, Perez M, Donastorg Y, Kerrigan D. Factors related to fertility 499 desire among female sex workers living with HIV in the Dominican Republic. BMC 500 Womens Health 2018; 18: 117. 501 40 Nattabi B, Li J, Thompson SC, Orach CG, Earnest J. A Systematic Review of Factors 502 503 Influencing Fertility Desires and Intentions Among People Living with HIV/AIDS: Implications for Policy and Service Delivery. AIDS Behav 2009; 13: 949-68. 504 41 Jin H, Restar A, Beyrer C. Overview of the epidemiological conditions of HIV among key 505 populations in Africa. J Int AIDS Soc 2021; 24: e25716. 506 42 Mumtaz GR, Chemaitelly H, AlMukdad S, et al. Status of the HIV epidemic in key 507 populations in the Middle East and north Africa: knowns and unknowns. Lancet HIV 2022: 508 **9**: e506–16. 509 43 Michele Saounde Temgoua E, Nguefeu Nkenfou C, Cecile Zoung-Kanyi Bissek A, et al. 510 HIV-1 Early Infant Diagnosis is an Effective Indicator of the Prevention of Mother-to-Child 511 Transmission Program Performance: Experience from Cameroon. Curr HIV Res 2015; 13: 512 286-91. 513 20

Harmonizing AIM estimates of PWLHIV

- 44 Domingues RMSM, Saraceni V, Leal M do C. Mother to child transmission of HIV in
- 515 Brazil: Data from the 'Birth in Brazil study', a national hospital-based study. *PLOS ONE* 516 2018; **13**: e0192985.
- ⁵¹⁷ 45 Sirirungsi W, Khamduang W, Collins IJ, *et al.* Early infant HIV diagnosis and entry to HIV ⁵¹⁸ care cascade in Thailand: an observational study. *Lancet HIV* 2016; **3**: e259–65.
- 46 Sibanda EL, Webb K, Fahey CA, *et al.* Use of data from various sources to evaluate and
 improve the prevention of mother-to-child transmission of HIV programme in Zimbabwe: a
 data integration exercise. *J Int AIDS Soc* 2020; 23: e25524.
- 47 Reniers G, Eaton J. Refusal bias in HIV prevalence estimates from nationally representative seroprevalence surveys. *AIDS Lond Engl* 2009; **23**: 621–9.
- 48 Saito S, Howard AA, Chege D, *et al.* Monitoring quality at scale: implementing quality assurance in a diverse, multicountry HIV program. *AIDS Lond Engl* 2015; **29**: S129–36.